JP2015505296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505296A5 JP2015505296A5 JP2014538931A JP2014538931A JP2015505296A5 JP 2015505296 A5 JP2015505296 A5 JP 2015505296A5 JP 2014538931 A JP2014538931 A JP 2014538931A JP 2014538931 A JP2014538931 A JP 2014538931A JP 2015505296 A5 JP2015505296 A5 JP 2015505296A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- represented
- alkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- -1 peptidyl compound Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- NSCGMRWMLGCCDO-YDALLXLXSA-N CCCC(N(C)[C@@](CC)(CCC)C(N)=O)[U] Chemical compound CCCC(N(C)[C@@](CC)(CCC)C(N)=O)[U] NSCGMRWMLGCCDO-YDALLXLXSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550782P | 2011-10-24 | 2011-10-24 | |
| US61/550,782 | 2011-10-24 | ||
| PCT/US2012/061696 WO2013063120A2 (en) | 2011-10-24 | 2012-10-24 | Nmda receptor modulators and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505296A JP2015505296A (ja) | 2015-02-19 |
| JP2015505296A5 true JP2015505296A5 (enExample) | 2015-11-26 |
| JP6210993B2 JP6210993B2 (ja) | 2017-10-11 |
Family
ID=48168770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538931A Active JP6210993B2 (ja) | 2011-10-24 | 2012-10-24 | Ｎｍｄａ受容体調節剤およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US8673843B2 (enExample) |
| EP (1) | EP2771021B1 (enExample) |
| JP (1) | JP6210993B2 (enExample) |
| KR (2) | KR101692275B1 (enExample) |
| CN (2) | CN109232713A (enExample) |
| AU (3) | AU2012328927B2 (enExample) |
| BR (1) | BR112014009851A8 (enExample) |
| CA (1) | CA2853364C (enExample) |
| ES (1) | ES2703904T3 (enExample) |
| HK (1) | HK1206616A1 (enExample) |
| RU (1) | RU2621049C2 (enExample) |
| SG (1) | SG11201401776WA (enExample) |
| WO (1) | WO2013063120A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| US9101612B2 (en) * | 2010-02-11 | 2015-08-11 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| PE20151438A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| KR20150110784A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| AU2014212484B2 (en) | 2013-01-29 | 2018-01-04 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam NMDA receptor modulators and uses thereof |
| EA032153B1 (ru) | 2013-01-29 | 2019-04-30 | Аптиникс Инк. | Спиролактамные модуляторы nmda-рецептора и их применение |
| AU2014212487C1 (en) | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| AU2014243773B2 (en) | 2013-03-13 | 2018-12-13 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| CN104109189B (zh) * | 2013-04-18 | 2019-05-10 | 中国人民解放军军事医学科学院毒物药物研究所 | Thr-Pro-Pro-Thr四肽的液相合成方法 |
| SG10201810496XA (en) * | 2013-10-28 | 2018-12-28 | Naurex Inc | Nmda receptor modulators and prodrugs, salts, and uses thereof |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016014982A1 (en) | 2014-07-24 | 2016-01-28 | Naurex, Inc. | N-methyl-d-aspartate receptor modulators and methods of making and using same |
| EP3204011A4 (en) * | 2014-10-07 | 2018-06-20 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| CA2991214C (en) | 2015-07-06 | 2024-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2016340080A1 (en) * | 2015-10-16 | 2018-05-10 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
| MA44526A (fr) | 2016-04-01 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PE20190174A1 (es) | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| MA45598B1 (fr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda |
| EP3490992B1 (en) | 2016-08-01 | 2023-03-22 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20190504A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos |
| SG11201900558RA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| CN109843889B (zh) | 2016-08-01 | 2022-03-15 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda调节剂和使用其的方法 |
| EA201990425A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| US11111266B2 (en) | 2016-10-18 | 2021-09-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN108148113A (zh) * | 2016-12-06 | 2018-06-12 | 深圳先进技术研究院 | 一种nmda受体调控剂四肽衍生物的固相合成方法 |
| CN107474107B (zh) * | 2017-05-18 | 2023-01-17 | 江苏恩华药业股份有限公司 | Glyx-13的制备方法及用于制备glyx-13的化合物 |
| FR3067028B1 (fr) * | 2017-06-06 | 2019-07-12 | Adpuerivitam | Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composes dans le traitement de maladies impliquant le systeme nerveux central |
| US20200199173A1 (en) * | 2017-07-28 | 2020-06-25 | Naurex, Inc. | Process and intermediates for synthesis of peptide compounds |
| CA3089561A1 (en) | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CN113480596A (zh) * | 2019-04-09 | 2021-10-08 | 北京广为医药科技有限公司 | 一种调节nmda受体活性的化合物、其药物组合物及用途 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683221A (en) * | 1986-01-09 | 1987-07-28 | Scripps Clinic And Research Foundation | Lymphocyte-activating polypeptides |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| WO1992007561A1 (en) | 1990-10-30 | 1992-05-14 | Ss Pharmaceutical Co., Ltd. | Antiphlogistic and analgesic gel preparation |
| JP3318622B2 (ja) * | 1992-05-27 | 2002-08-26 | 独立行政法人産業技術総合研究所 | プロリルエンドペプチダーゼ阻害剤 |
| FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
| SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US6541453B2 (en) | 1996-06-07 | 2003-04-01 | Syngenta Limited | Peptide derivatives |
| EP0918859A1 (en) | 1996-08-02 | 1999-06-02 | ZymoGenetics, Inc. | Testis-specific insulin homolog polypeptides |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
| EP0990051A1 (en) * | 1997-07-07 | 2000-04-05 | Florida State University | Identification of molecular targets |
| US6897028B1 (en) * | 1997-07-07 | 2005-05-24 | Florida State University | Identification of molecular targets |
| WO1999024584A1 (en) | 1997-11-12 | 1999-05-20 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
| US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
| US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
| US6902886B1 (en) * | 1998-11-06 | 2005-06-07 | The Research Foundation Of State University Of New York | Genetic assay for protein nuclear transport |
| US6194158B1 (en) | 1998-11-12 | 2001-02-27 | Nyxis Neurotherapies, Inc. | Diagnostic assay for cancer |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| WO2001036685A2 (en) | 1999-11-17 | 2001-05-25 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
| WO2001057240A2 (en) | 2000-02-01 | 2001-08-09 | Agy Therapeutics, Inc. | Interaction of nmda receptor with protein tyrosine phosphatase |
| WO2001096606A2 (en) | 2000-06-14 | 2001-12-20 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
| WO2001098367A2 (en) | 2000-06-22 | 2001-12-27 | Nyxis Neurotherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| US20020142287A1 (en) | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
| US20030065138A1 (en) | 2001-03-07 | 2003-04-03 | University Of Utah Research Foundation | Linear gamma-carboxyglutamate rich conotoxins |
| AU2002255705A1 (en) | 2001-03-12 | 2002-09-24 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| MXPA03010762A (es) * | 2001-05-31 | 2005-03-07 | Univ Princeton | Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap. |
| US20030022253A1 (en) * | 2001-07-25 | 2003-01-30 | Nyxis Neurotherapies, Inc. | Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| WO2005014797A2 (en) | 2003-08-08 | 2005-02-17 | The Burnham Institute | P16 mediated regulation of nmda receptors |
| WO2005020973A2 (en) | 2003-08-29 | 2005-03-10 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| US7951912B2 (en) | 2005-08-26 | 2011-05-31 | Wisconsin Alumni Research Foundation | Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same |
| US8507439B2 (en) | 2005-08-29 | 2013-08-13 | Angela Shashoua | Neuroprotective and neurorestorative method and compositions |
| US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| MX2009002921A (es) | 2006-09-15 | 2009-04-01 | Schering Corp | Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico. |
| CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
| CN101317844B (zh) * | 2007-06-08 | 2010-11-17 | 章劲夫 | 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用 |
| CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
| WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
| BRPI0916609A2 (pt) | 2008-08-07 | 2015-08-04 | Hoffmann La Roche | Processo para a preparação de um macrociclo |
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| CN102316886B (zh) * | 2008-12-15 | 2014-06-18 | 可尔必思株式会社 | 抗皮肤老化肽 |
| WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| EP2485751B1 (en) | 2009-10-05 | 2014-05-21 | Northwestern University | GLYX-13 for use in a method of treating refractory depression |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| US9101612B2 (en) | 2010-02-11 | 2015-08-11 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| KR20210046843A (ko) | 2011-04-27 | 2021-04-28 | 노오쓰웨스턴 유니버시티 | 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 |
| US8795919B2 (en) | 2011-11-29 | 2014-08-05 | Societe BIC & Sanyo Electric Co., Ltd. | Fuel cell layer |
-
2011
- 2011-02-11 KR KR1020127023731A patent/KR101692275B1/ko not_active Expired - Fee Related
-
2012
- 2012-06-18 US US13/525,861 patent/US8673843B2/en active Active
- 2012-10-24 SG SG11201401776WA patent/SG11201401776WA/en unknown
- 2012-10-24 WO PCT/US2012/061696 patent/WO2013063120A2/en not_active Ceased
- 2012-10-24 ES ES12844456T patent/ES2703904T3/es active Active
- 2012-10-24 JP JP2014538931A patent/JP6210993B2/ja active Active
- 2012-10-24 EP EP12844456.9A patent/EP2771021B1/en active Active
- 2012-10-24 AU AU2012328927A patent/AU2012328927B2/en active Active
- 2012-10-24 CN CN201810978925.1A patent/CN109232713A/zh active Pending
- 2012-10-24 CA CA2853364A patent/CA2853364C/en active Active
- 2012-10-24 US US14/353,681 patent/US20150051262A1/en not_active Abandoned
- 2012-10-24 KR KR1020147013898A patent/KR102038161B1/ko active Active
- 2012-10-24 RU RU2014121090A patent/RU2621049C2/ru active
- 2012-10-24 CN CN201280063834.6A patent/CN104321071A/zh active Pending
- 2012-10-24 HK HK15107208.6A patent/HK1206616A1/xx unknown
- 2012-10-24 BR BR112014009851A patent/BR112014009851A8/pt not_active Application Discontinuation
-
2014
- 2014-01-23 US US14/162,328 patent/US20150315237A1/en not_active Abandoned
-
2016
- 2016-08-30 US US15/252,132 patent/US20160368947A1/en not_active Abandoned
-
2017
- 2017-08-14 AU AU2017213587A patent/AU2017213587A1/en not_active Abandoned
-
2018
- 2018-02-14 US US15/896,662 patent/US20180237474A1/en not_active Abandoned
- 2018-07-06 US US16/028,664 patent/US20190135862A1/en not_active Abandoned
-
2019
- 2019-06-11 AU AU2019204073A patent/AU2019204073B2/en active Active